pipeline

ABL Bio is the only biotech company in Korea with a bispecific antibody platform that is undergoing clinical trial.

  • ABL001
    Dual VEGF/DLL4 Inhibition
    Overcomes VEGF Therapy
    Resistance
    ABL001 is a bispecific antibody drug that targets both VEFG and DLL4, thereby inhibiting new tumor vessel formation.
  • IMMUNO-ONCOLOGY
    Cancer Immunotherapy
    T-cell engager immuno-oncology pipeline, a technology that has been transferred to TRIGR in the amount of $550 million.
  • ADC
    For A Better ADC
    Developing drugs for rare blood cancers by adopting ADC therapeutics.
  • ABL301
    Targeting Aggregated
    A-synuclein by ABL301
    The goal for ABL301 is the cure of Parkinson’s Disease, a major illness of neurodegenerative disease.

MORE

Notice & News

Latest News on ABL Bio

NEWS

ABL Bio, Announces BCMAx4-1BB Bispecific...

2019-12-10

ABL Bio, Announces BCMAx4-1BB Bispecific Antibody Superb Efficacy Compared to Bispecific An...

View more

NEWS

ABL Bio Announces Strategic Partnership ...

2018-07-26

ABL Bio Announces Strategic Partnership with I-Mab Biopharma of China- Joint Development o...

View more

NEWS

ABL Bio Adopts Novel Bispecific Antibody...

2018-02-25

​ABL Bio Adopts Novel Bispecific Antibody PlatformandTwo Types of Immuno-Oncology Targeted...

View more

MORE

INVESTOR RELATIONS

Information on ABL Bio's IR

career

ABL Bio History

ABL Bio

2019

  • 01. 01

    No. 1 Biotech in Korea

  • 01. 01

    Became the leader among biotech firms in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases using bispecific antibody.

2018

  • 01. 01

    Series C Funding (paid-in capital of 70 billion KRW, June)

  • 01. 01

    Multiple contracts on bispecific antibody program and technology transfer

  • 01. 01

    IPO on KOSDAQ, Dec. 19, 2018 (90 billion KRW of public offering)

MORE